The discovery could be the answer to why some people are more likely to develop a devastating lung disease – idiopathic pulmonary fibrosis (IPF).
News
ViiV, UNC-Chapel Hill renew HIV partnership for another five years
Since 2015, the first-of-its-kind collaboration has brought together academic and pharmaceutical industry researchers to create a deeper understanding of how HIV works.
Finalists announced for the 2020 International Clinical Researcher of the Year competition
Find out which individuals and teams will be putting their skills to the test in the live finals days later this year.
Breast cancer ‘breakthrough’ could end unnecessary biopsies
The novel mammography imaging system could potentially “spell an end” to unnecessary biopsies, by determining benign or malignant breast lesions.
EU Marketing Authorisation change for Maviret
The authorisation shortens the treatment period from from 12 to eight weeks.
3000 more babies saved by NHS actions
The extra lives saved between 2010 and 2018 means that the NHS has met its own ambitious 20% target two years ahead of the 2020 deadline.
COVID-19: Updates from Mologic, Gilead, CEPI
With the outbreak at “critical juncture”, analysts are saying Gilead’s remdesivir stands a 50% chance of success as a vaccine.
£200m mental health crisis services rolled out across England
Another £140 million will then be used to bolster the services further from 2021 onwards.
97% of UK pharmacists expect ‘great pressure’ in 2020
Key issues mentioned were complex working processes between pharmacies and GP practices, handling prescriptions and management of patient records.
Imfinzi cancer combo falls short in DANUBE trial
Despite the setback, AstraZeneca says that it “remains committed to addressing unmet needs in bladder cancer.”
Post-surgery chemo halves risk of recurring rare kidney cancer
71% of patients given chemotherapy survived for three years or more after joining the trial without their disease coming back, compared with 46% of patients who were on surveillance.
NICE pushes Doptelet for pre-surgery liver disease treatment
Last year, the therapy received a positive opinion from the EMA’s CHMP.
Sanofi, Babylon link-up to tackle digestive health
Only an estimated 30% of people in the UK who suffer from IBS have actually been diagnosed and, of those, 61% often mistreat their symptoms with analgesics or antacids.
Givlaari approved in EU following recent CHMP nudge
The drug is a first-of-its kind injectable RNAi therapeutic.
Orphan drugs face “uphill battle” in 2020
EMA-assigned Orphan Drug Designations declined 49% between 2014 and 2019.
